ITGB1基因在WHO 2级及3级胶质瘤患者的表达及其预后价值研究

文才 李(桂林医学院附属医院，中国)
学巍 夏(桂林医学院附属医院，中国)

摘要

目的：胶质瘤是中枢神经系统中最常见的恶性肿瘤，我们通过生物学信息分析WHO 2级及3级胶质瘤患者ITGB1基因表达，研究其在低级别胶质瘤中的预后价值。方法：从TCGA数据库中下载患者ITGB1基因表达量及临床数据，采用统计学方法比较WHO 2级及3级患者中基因表达差异及ITGB1基因和临床参数与患者的预后关系。结果：WHO3级胶质瘤患者中ITGB1基因的表达水平高于2级胶质瘤（P＜0.05）。KM生存分析显示，ITGB1低表达组的总体生存率明显优于高表达组（P＜0.05）。COX单因素及多因素分析，ITGB1基因、年龄是2级和3级胶质瘤患者的独立危险因素（校正P=0.029；校正HR=0.383；95%CI:0.162-0.907）。结论：基于TCGA数据库研究结果提示ITGB1基因可能是WHO 2级及3级胶质瘤患者预后的分子标记物，但仍需要在更进一步实验验证。

关键词

胶质瘤；ITGB1基因；TCGA数据库；分子靶点

参考

JEMAL A,SIEGEL R,XU J Q,et al. Cancer statistics [J] .CA Cancer J Clin, 2010, 60: 277-300.

KANG J H,ADAMSON C,Novel chemotherapeutics and other therapies for treating high-grade glioma [J] .Expert Opin Investig Drugs, 2015, 24: 1361-79.

MILLER J J,WEN P Y.Emerging targeted therapies for glioma [J].Expert Opin Emerg Drugs, 2016, 21: 441-452.

CHUNTOVA P,DOWNEY K M,HEGDE B,et al. Genetically Engineered T-Cells for Malignant Glioma: Overcoming the Barriersto Effective Immunotherapy [J] .Front Immunol, 2018, 9: 3062.

RAMEZANI S,VOUSOOGHI N,JOGHATAEI M T,et al. The Role of Kinase Signaling in Resistance to Bevacizumab Therapy for Glioblastoma Multiforme [J] .Cancer Biother Radiopharm, 2019, 34: 345-354.

CARBONELL W S,DELAY M,JAHANGIRI A,et al. β1 integrin targeting potentiates antiangiogenic therapy and inhibits the growth of bevacizumab-resistant glioblastoma [J] .Cancer Res, 2013, 73: 3145-54.

ZHANG J X,LIU K C,PENG P,et al. Upregulation of nectin-4 is associated with ITGB1 and vasculogenic mimicry and may serve as a predictor of poor prognosis in colorectal cancer [J] .Oncol Lett, 2019, 18: 1163-1170.

SLOAN A E,OKADA H,RYKEN T C,et al. The role of emerging therapy in the management of patients with diffuse low grade glioma [J] .J Neurooncol, 2015, 125: 631-5.

AlTAMIMI Y Z,PALIN M S,PATANKAR T,et al. Low-Grade Glioma with Foci of Early Transformation Does Not Necessarily Require Adjuvant Therapy After Radical Surgical Resection [J] .World Neurosurg, 2018, 110: e346-e354.

WANG J,CAI C,NIE D K,et al. FRK suppresses human glioma growth by inhibiting ITGB1/FAK signaling [J] .Biochem Biophys Res Commun, 2019, 517: 588-595.

YANG W J,XIE T.Hsa_circ_CSPP1/MiR-361-5p/ITGB1 Regulates Proliferation and Migration of Cervical Cancer (CC) by Modulating the PI3K-Akt Signaling Pathway [J] .Reprod Sci, 2020, 27: 132-144.

DAI L,CHAI C M,SHEN T Y,et al. LncRNA ITGB1 promotes the development of bladder cancer through regulating microRNA-10a expression [J] .Eur Rev Med Pharmacol Sci, 2019, 23: 6858-6867.

WU R T,GAO Y,WU J Q,et al. Semi-synthetic product dihydroartemisinin inhibited fibronectin-1 and integrin-β1 and interfered with the migration of HCCLM6 cells via PI3K-AKT pathway [J] .Biotechnol Lett, 2020, 42: 917-926.

REN L L,MO W J,WANG L L,et al. Matrine suppresses breast cancer metastasis by targeting ITGB1 and inhibiting epithelial-to-mesenchymal transition [J] .Exp Ther Med, 2020, 19: 367-374.

BALTES F,PFEIFER V,SILBERMANN K,et al. β-Integrin binding to collagen type 1 transmits breast cancer cells into chemoresistance by activating ABC efflux transporters [J] .Biochim Biophys Acta Mol Cell Res, 2020, 1867: 118663.

WANTOCHVON R K,KONIG P,HENZE S,et al. The Impact of Integrin-Mediated Matrix Adhesion on Cisplatin Resistance of W1 Ovarian Cancer Cells [J] .Biomolecules, 2019, 9.

DOI: http://dx.doi.org/10.26549/yzlcyxzz.v4i1.6446